There remains high unmet medical needs for rare diseases. Patients and their families are constantly seeking new and/or alternative treatments for these conditions. However, challenges to patient recruitment, patient care/treatment, and market size are major hurdles for sponsors who pursue development of new therapies for rare diseases. Successful orphan drug development requires medical and scientific understanding of the disease, both short and long term strategy, commitment, and passion.
Azelix is able and committed to working together with you to make a difference for patients suffering from rare diseases. We can leverage the expertise of our strategic partners globally if additional expertise is needed due to the nature of rare disease indications. Our extensive investigator database allows us to help you pinpoint geographic regions to identify patients for the target orphan disease. Our goal is to maintain an open and collaborative relationship with our trusted partners to help bring better therapies to those patients who need them most.